Our Company

Aileron Therapeutics (NASDAQ:ALRN) is the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases.

Advisory Board

×
Advisor

Brian Druker, M.D.

Director, Knight Cancer Institute, Oregon Health and Science School of Medicine, JELD-WEN Chair of Leukemia Research; Investigator, Howard Hughes Medical Institute

×
Advisor

Robert H. Grubbs, Ph. D.

Victor and Elizabeth Atkins Professor of Chemistry, California Institute of Technology; Nobel Prize Laureate for Chemistry in 2005.

×
Advisor

Alan List, M.D.

President and CEO, Moffitt Cancer Center; Senior Member in the Department of Malignant Hematology and the Experimental Therapeutic Program, Professor of Internal Medicine and Oncology, University of South Florida Morsani College of Medicine

×
Advisor

Carol Prives, Ph. D.

DaCosta Professor of Biological Sciences, Columbia University

×
Advisor

Ulrich Steidl, M.D., PH. D.

Professor, Department of Cell Biology and Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine – Montefiore Medical Center